Agustina Zambernardi; Rosa María Papale; Inés Bignone

Authors

Agustina Zambernardi Ramos Mejía Hospital, Autonomous City of Buenos Aires, Argentina
Rosa María Papale Administration of Medicines, Food and Medical Technology, Autonomous City of Buenos Aires, Argentina
Inés Bignone University of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Keywords:

adverse drugs reaction, notification of lack of drugs efficacy, notification of adverse drugs effects

Abstract

Spontaneous notification of adverse drugs effects or the lack of drugs efficacy are very important public health issues. They allow sharing information and taking appropriate regulatory measures for the safe use of medicines. Although adverse drug reactions have different manifestations, cutaneous involvement is the most frequent, so that it specially involves us as Dermatologists. Our goal is to inform colleagues about the National Pharmacovigilance System, to raise awareness of the importance of notifying adverse drugs effects.

Author Biographies

Agustina Zambernardi, Ramos Mejía Hospital, Autonomous City of Buenos Aires, Argentina

Physician, Municipal Concurrent in Dermatology, Working Group on Adverse Drug Reactions of the Argentine Society of Dermatology

Rosa María Papale, Administration of Medicines, Food and Medical Technology, Autonomous City of Buenos Aires, Argentina

Specialist in Pediatrics. Specialist in Dermatology. Head of the ANMAT Pharmacovigilance Department. Working Group on Adverse Drug Reactions of the Argentine Society of Dermatology

Inés Bignone, University of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Professor and Doctor of Medicine. Pharmacologist, ANMAT

References

I. World Health Organization. Guidelines on Hand Hygiene in Health Care. First Global Patient Safety Challenge Clean Care Is Safer Care. [en línea]. Geneva; 2009. <https://www.ncbi.nlm.nih.gov/books/NBK144013>[consulta 3 de mayo de 2018].ISBN-13:978-92-4-159790-6.

II. Olsson S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf 1998;19:1-10.

III. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies. Drug Safety 2015;38:437-453.

IV. Ministerio de Salud de la Nación, Secretaría de Políticas, Regulación e Institutos ANMAT. Disposición 5358/2012. Buenas Prácticas de Farmacovigilancia [en línea], Boletín Oficial ANMAT, septiembre de 2012. <http://www.anmat.gov.ar/boletin_anmat/septiembre_2012/Dispo_5358-12.pdf> [consulta 3 de mayo de 2018].

V. Papale RM. Reacciones adversas a drogas. Otros aspectos. Dermatol Argent 2010;16:72-74.

VI. Ministerio de Salud de la Nación, Secretaría de Políticas, Regulación e Institutos ANMAT, Circular 008/2009. Guía de Buenas Prácticas de Farmacovigilancia [en línea], Boletín Oficial ANMAT, noviembre de 2009 <http://www.anmat.gov.ar/boletin_anmat/BO/bpfv_circular_008_2009.pdf.>. [consulta 3 de mayo de 2018].

VII. World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. [en línea]. WHO Policy Perspectives on Medicines. Issue No. 9, October 2004. <http://www.who.int/medicines/publications/policyperspectives/en/>, [consulta 3 de mayo de 2018].